New Insights into the Role of Metformin Effects on Serum Omentin-1 Levels in Acute Myocardial Infarction: Cross-Sectional Study

Abstract

Background. Serum omentin-1 level was low in the most types of ischemic heart disease compared to normal subjects; it also dependently correlated with coronary heart disease; thus, omentin-1 is regarded as a novel biomarker in IHD. Objective. The aim of the present study was to establish the links between omentin-1 and acute myocardial infarction in metformin patients. Subjects and Methods. A cross-sectional study was performed on eighty-five patients with type II DM and acute MI. They are divided as follows: Group I, 62 patients with type II DM who received metformin prior to onset of acute MI; Group II, 23 patients with type II DM who did not receive metformin prior to onset of acute MI; and Group III, 30 normal healthy controls. Venous blood was drawn from each participant for determination of lipid profile, plasma omentin-1, cardiac troponin-I (cTn-I) and other routine tests. Results. Patients that presented with acute MI that received metformin show a significant difference in all biochemical parameters (p < 0.001); metformin increases serum omentin-1 level and decreases serum cardiac troponin-I level compared with control subjects and nonmetformin treated patients. Conclusion. Metformin pharmacotherapy increases omentin-1 serum levels and may be regarded as a potential agent in the prevention of the occurrences of acute MI in diabetic patients.

Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: Concepts and clinical practice

“…[ 1 ] T2DM is a metabolic disorder associated with numerous adipocytokine changes which may play an important role in the progression of insulin resistance and micro- and macro-vascular complications. [ 2 ] Most of the adipocytokines are synthesized and secreted by adipocytes such as leptin, omentin-1, and adiponectin[ 3 ] in patients with T2DM; there are significant changes in visceral adiposity and gluco-lipid metabolism that per se lead to adipocytokine dysregulation. [ 4 ]…”

Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins

“…[26,27] Regarding other treatment for patients presented with acute MI, metformin drug was used in 57.65% of our patients due to type 2 DM, thus reduction in ASP levels might be due to metformin effects as observed by Oktenli et al, study that revealed a significant reduction in ASP levels in women patients with polycystic ovary syndrome following 3 months therapies with metformin; [28] however, the selected effect of metformin on ASP levels was not estimated at the present study since; we have a previous study regarding the cardioprotective effect of metformin in patients presented with acute MI that previously treated with metformin. [29] ASP levels were negatively correlated with LDL cholesterol (LDL-c), HDL-c, and TC in both statins-and nonstatins-treated patients with acute MI, and positively correlated with other lipid profile and anthropometric variables, these findings are correlated with Jiang et al, findings that revealed a significant association and correlation between high serum ASP levels and total TG and BMI with significant negative correlation with LDL-c, HDL-c, and TC in diabetic obese patients regarding Han and Hui populations. [30] Furthermore, ASP levels were positively correlated with cTnI in patients with acute MI regardless of statins therapy, since ASP levels are positively correlated with severity of CAD and cTnI indicating that ASP is implicated in pathogenesis of CAD due to metabolic alterations in lipid profile.…”

Omentin – a novel biomarker in medicine? (Part 2)

“…Wydaje się, że wzrost stężenia omentyny-1 we krwi w warunkach niedokrwienia mięśnia sercowego jest zjawiskiem wtórnym i ma działanie ochronne. Farmakoterapia metforminą powodująca wzrost stężenia omentyny-1 we krwi, która działa kardioprotekcyjnie, może być zastosowana u pacjentów z cukrzycą typu 2 jako potencjalny środek zapobiegawczy wystąpienia ostrego zawału mięśnia sercowego [10].…”